CER Daily Newsfeed

Video: Real-World Evidence in Treatment Selection: Luspatercept vs ESAs in Clinical Practice

(7/11, Saeed Sadeghi, MD, Targeted Oncology) “A panelist emphasizes that recent real-world retrospective data from 103 first-line luspatercept-treated patients closely align with, and even slightly exceed, COMMANDS trial results—demonstrating significant hemoglobin improvements and transfusion independence—thereby reinforcing luspatercept’s effectiveness and practical value in routine clinical care for erythropoiesis-stimulating agent–naïve, low-risk patients with myelodysplastic syndrome.” View Video

Enabling Real-World Evidence Through Trusted Research Environments: Insights from the SAIL Databank

(7/11, Katie McCool, The Evidence Base) reports “...Ashley Akbari (Professor of Population Data Science Research at Population Data Science, Swansea University) presented the Secure Anonymised Information Linkage (SAIL) Databank, the national TRE for Wales, highlighting how anonymized, linkable datasets are used to support multidisciplinary research aimed at improving services and outcomes...To support consistency in RWD research, SAIL is investing in reproducible workflows and harmonized data assets. This includes work to standardize phenotype definitions and develop research-ready data assets (RRDAs), which can be provisioned for future studies.” Full